Roche Holding AG RHHBY:OTCQX International Premier (Depositary Receipt)
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
|---|---|---|---|---|
| 35.66 | 0.46 1.31% | 3.15% | 615,749 | 1.6M |
Latest News Headlines for Roche Holding AG
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--October 08, 2014-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted to file the company's supplemental Biologics License Application (sBLA) and granted Priority Review of Lucentis(R) (ranibizumab injection) for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7 million Americans. The FDA confirmed action date is February 6, 2015.
Ventana is committed to accelerating the discovery and development of new cancer diagnostic tests that help determine the best course of therapy for each individual patient. MOUNTAIN VIEW, Calif., Sept. 30, 2014 /PRNewswire/ -- Based on its recent analysis of the oncology tissue diagnostics market, Frost & Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, with the 2014 North American Frost & Sullivan Award for Technology Innovation Leadership. Adherence to strict quality practices along with a focus on innovation and improving patient safety have made Ventana a global leader in tissue-based cancer diagnostic solutions for patients worldwide.
-- Cobimetinib plus Zelboraf reduced the risk of disease worsening by half compared to Zelboraf alone -- Phase III coBRIM study results will be presented today during the
Company Background
Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. It belongs to the Roche Group that operates through subsidiaries and associated companies. It discovers, develops and provides diagnostic and therapeutic products and services from early detection and prevention of diseases to diagnosis, treatment and treatment monitoring. The Company has two divisions: Pharmaceuticals and Diagnostics. It operates worldwide containing the United States, Western Europe, Japan, Latin America and Asia-Pacific, among others. Diagnostics include five business areas: Applied Science, Diabetes Care, Molecular Diagnostics, Tissue Diagnosis and Professional Diagnostics. It operates in five geographical regions: Europe, Middle East and Africa (EMEA); North America; Asia-Pacific; Latin America, and Japan. In September 2014, it accepted for payment of all shares of InterMune Inc. through its wholly owned subsidiary Klee Acquisition Corporation.
collapse, right-facing arrow indicating collapsed view of sectionOverview
| Bid | Size | -- | -- |
|---|---|
| Ask | Size | -- | -- |
| Price Open | 35.115 |
| Previous Close | 35.20 |
| Day High | 35.725 |
| Day Low | 35.05 |
| 52 Week High | 2/28/2014 | 38.71 |
| 52 Week Low | 10/9/2013 | 31.75 |
| % Off 52 Week High | -7.88% |
| % Off 52 Week Low | 12.31% |
| Beta (5 Yr) | 0.6 |
| Volatility Avg | 10/7/2014 | 17.21 |
| 10-Day Avg. Volume | 1,628,744 |
| Market data is delayed by at least 20 minutes. | |
collapse, right-facing arrow indicating collapsed view of sectionFundamentals
| EPS (TTM) | 6/30/2014 | 1.63 |
|---|---|
| P/E Ratio | 6/30/2014 | 21.6 |
| Market Cap | Large Cap | 196.7B |
| Shares Outstanding | 5.52B |
| Float | 5.6B |
collapse, right-facing arrow indicating collapsed view of sectionDividends
| Dividend Yield | 3.15% |
|---|---|
| Ex-Date | 3/6/2014 |
| Dividend Announcement | 2/27/2014 |
| Date of Record | 3/10/2014 |
| Payable | $1.109 - ANN |
| Payable Date | 4/22/2014 |
Peers Information HelpRHHBY Roche Holding AG vs. Peers
| Peers | |
|---|---|
RHHBY Roche Holding AG | 0.28% |
Johnson & Johnson | 11.79% |
Abbott Laboratories | 8.17% |
Merck & Co., Inc. | 16.80% |
Bristol-Myers Squibb Co | -6.36% |
RHHBY Roche Holding AG | 3.11% |
Johnson & Johnson | 2.73% |
Abbott Laboratories | 2.12% |
Merck & Co., Inc. | 3.01% |
Bristol-Myers Squibb Co | 2.89% |
RHHBY Roche Holding AG | 1.31% |
Johnson & Johnson | 2.46% |
Abbott Laboratories | 1.64% |
Merck & Co., Inc. | 2.94% |
Bristol-Myers Squibb Co | 0.88% |